Triple-modality therapy maximizes antitumor immune responses in a mouse model of mesothelioma-Reference-Cited by-同舟云学术

Triple-modality therapy maximizes antitumor immune responses in a mouse model of mesothelioma

Published:2021-04-14 Issue:589 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Murakami Junichi¹²,Wu Licun¹^ORCID,Kohno Mikihiro¹³,Chan Mei-Lin¹^ORCID,Zhao Yidan¹^ORCID,Yun Zhihong¹^ORCID,Cho B. C. John⁴^ORCID,de Perrot Marc¹³⁵^ORCID

Affiliation:

1. Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario M5G 1L7, Canada.

2. Department of Surgery and Clinical Science, Division of Chest Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.

3. Division of Thoracic Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2C4, Canada.

4. Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2C1, Canada.

5. Department of Immunology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.

Abstract

Combining IL-15 superagonist and anti-GITR agonist therapy enhances antitumor effects of radiation therapy in a mouse model of mesothelioma.

Funder

Uehara Memorial Foundation

Princess Margaret Cancer Foundation

Toronto General and Western Hospital Foundation

Canadian Mesothelioma Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference61 articles.

1. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

2. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

3. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

4. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis

5. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model;Radiotherapy and Oncology;2024-01

2. Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy;Cancer Immunology Research;2023-08-04

3. Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers;Molecular Cancer Therapeutics;2023-05-04

4. Emerging Role of Immunomonitoring to Predict the Clinical Outcome of Patients With Malignant Pleural Mesothelioma Treated With Radical Radiation Therapy;International Journal of Radiation Oncology*Biology*Physics;2023-03

5. Defining and targeting tumor-associated macrophages in malignant mesothelioma;Proceedings of the National Academy of Sciences;2023-02-23